(Reuters) – AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company’s initial stage T-cell engager. The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)